Skip to content

Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence

Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03239964
Enrollment
146
Registered
2017-08-04
Start date
2016-08-10
Completion date
2018-01-24
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keloid

Keywords

recurrent keloid, surgical excision, steroids injection

Brief summary

Two groups of patients (73 patients each) undergoing routine caesarean section has recurrent keloid at site of surgical scar. One group will undergo surgical excision of keloid. The other group will have combined surgical excision of keloid and single intralesional dexamethasone injection at edges of wound.All patients were reviewed once per month for 6 months for evidence of recurrence

Detailed description

One hundred forty six patients that are admitted at Kasr Al Aini teaching university hospital for caesarean section, will be enrolled in this randomized clinical trial after approval by the local ethical health committee. A written informed consent will be obtained from each participant after full explanation of the procedure. Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of the keloid is performed and minimal undermining followed by the usual steps of caesarean section. Primary closure of the wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. In 73 patients (group B), the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. For all patients, the wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed. Postoperative medications are given to all patients in the form of analgesics and antibiotics as routinely given at the hospital. All patients were advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) were used in any of the patients. All patients were reviewed once per month for 6 months.

Interventions

DRUGDexamethasone

the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.

total extralesional surgical excision of the keloid is performed and minimal undermining

Sponsors

Kasr El Aini Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Documented keloids of pfannenstiel incision or midline subumbilical incision of one to five years duration. * Previous treatment of keloid and recurrence. * Patient complaint of cosmetic disfiguring, pain or pruritis at site of scar.

Exclusion criteria

* Scar \<1 years' duration * Scar extending beyond the limits of the original lesion * postburn keloids * Diabetes Mellitus, anaemia (haemoglobin level \<10mg/dL), malignancy, malnutrition. * local inflammation at site of scar * Allergy to dexamethasone. * Immunocompromized patients or patients on chronic steroid treatment.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with recurrent lesions6 monthssame/smaller/larger than pretreatment lesion

Secondary

MeasureTime frameDescription
Number of participantsc with pruritis6 monthsitching sensation at the site of wound
Number of participants with residual postinflammatory hyperpigmentation -burning sensation -wound dehiscence6 monthsredness or coloured pigmentation at wound site
Number of participants with burning sensation6 monthsfeel burn at wound site
Number of participants with wound dehiscence(complete)6 monthsarea of gaping of wound that requires secondary sutures
Number of participants with wound dehiscence(partial)6 monthsarea of gaping of wound that requires frequent dressings only

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026